| Autor: |
Campagna D; Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy.; UOC di Medicina Interna e d'Urgenza, Edificio 4, Piano 3, Azienda Ospedaliero-Universitaria 'Policlinico-V. Emanuele', Catania, Italy., Amaradio MD; Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy.; UOC di Medicina Interna e d'Urgenza, Edificio 4, Piano 3, Azienda Ospedaliero-Universitaria 'Policlinico-V. Emanuele', Catania, Italy., Sands MF; Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY USA.; The Veterans Administration Healthcare System of Western New York, Buffalo, NY USA., Polosa R; Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy.; UOC di Medicina Interna e d'Urgenza, Edificio 4, Piano 3, Azienda Ospedaliero-Universitaria 'Policlinico-V. Emanuele', Catania, Italy. |
| Abstrakt: |
Abstaining from tobacco smoking is likely to lower the risk of respiratory infections and pneumonia. Unfortunately, quitting smoking is not easy. Electronic cigarettes (ECs) are emerging as an attractive long-term alternative nicotine source to conventional cigarettes and are being adopted by smokers who wish to reduce or quit cigarette consumption. Also, given that the propylene glycol in EC aerosols is a potent bactericidal agent, switching from smoking to regular vaping is likely to produce additional lung health benefits. Here, we critically address some of the concerns arising from regular EC use in relation to lung health, including respiratory infections and pneumonia. In conclusion, smokers who quit by switching to regular ECs use can reduce risk and reverse harm from tobacco smoking. Innovation in the e-vapour category is likely not only to further minimise residual health risks, but also to maximise health benefits. |
Full text from SpringerLink